Simulations Plus (NASDAQ:SLP) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday.
Other analysts have also issued research reports about the stock. ValuEngine lowered shares of Simulations Plus from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 11th. Zacks Investment Research upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Saturday, July 21st.
NASDAQ SLP traded up $0.02 during mid-day trading on Friday, reaching $20.42. 23,604 shares of the stock were exchanged, compared to its average volume of 61,088. Simulations Plus has a 1-year low of $14.25 and a 1-year high of $23.95. The firm has a market cap of $354.59 million, a P/E ratio of 51.05 and a beta of -0.73.
In other Simulations Plus news, Chairman Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction on Monday, August 27th. The shares were sold at an average price of $20.33, for a total value of $376,105.00. Following the transaction, the chairman now owns 5,436,408 shares in the company, valued at approximately $110,522,174.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 55,500 shares of company stock worth $1,114,810. 33.45% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Advisors LLC acquired a new position in shares of Simulations Plus in the 2nd quarter valued at $129,000. Bank of Montreal Can acquired a new position in shares of Simulations Plus during the 2nd quarter valued at $186,000. TIAA FSB acquired a new position in shares of Simulations Plus during the 2nd quarter valued at $225,000. Acadian Asset Management LLC acquired a new position in shares of Simulations Plus during the 2nd quarter valued at $233,000. Finally, Rhumbline Advisers acquired a new position in shares of Simulations Plus during the 2nd quarter valued at $246,000. Institutional investors own 35.77% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Story: What kind of dividend yield to CEF’s pay?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.